These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 24851119)

  • 1. Duloxetine, a Selective Noradrenaline Reuptake Inhibitor, Increased Plasma Levels of 3-Methoxy-4-hydroxyphenylglycol but Not Homovanillic Acid in Patients with Major Depressive Disorder.
    Atake K; Yoshimura R; Hori H; Katsuki A; Ikenouchi-Sugita A; Umene-Nakano W; Nakamura J
    Clin Psychopharmacol Neurosci; 2014 Apr; 12(1):37-40. PubMed ID: 24851119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Catechol-O-methyltransferase Val158Met genotype and the clinical responses to duloxetine treatment or plasma levels of 3-methoxy-4-hydroxyphenylglycol and homovanillic acid in Japanese patients with major depressive disorder.
    Atake K; Yoshimura R; Hori H; Katsuki A; Nakamura J
    Neuropsychiatr Dis Treat; 2015; 11():967-74. PubMed ID: 25897233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum levels of brain-derived neurotrophic factor (BDNF), BDNF gene Val66Met polymorphism, or plasma catecholamine metabolites, and response to mirtazapine in Japanese patients with major depressive disorder (MDD).
    Katsuki A; Yoshimura R; Kishi T; Hori H; Umene-Nakano W; Ikenouchi-Sugita A; Hayashi K; Atake K; Iwata N; Nakamura J
    CNS Spectr; 2012 Sep; 17(3):155-63. PubMed ID: 22883353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma levels of IL-6 in patients with untreated major depressive disorder: comparison with catecholamine metabolites.
    Yoshimura R; Kishi T; Iwata N
    Neuropsychiatr Dis Treat; 2019; 15():2655-2661. PubMed ID: 31686824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum Brain-Derived Neurotrophic Factor, and Plasma Catecholamine Metabolites in People with Major Depression: Preliminary Cross-Sectional Study.
    Yoshimura R; Kishi T; Atake K; Katsuki A; Iwata N
    Front Psychiatry; 2018; 9():52. PubMed ID: 29541037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-frequency repetitive transcranial magnetic stimulation improves refractory depression by influencing catecholamine and brain-derived neurotrophic factors.
    Yukimasa T; Yoshimura R; Tamagawa A; Uozumi T; Shinkai K; Ueda N; Tsuji S; Nakamura J
    Pharmacopsychiatry; 2006 Mar; 39(2):52-9. PubMed ID: 16555165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Serum Brain-Derived Neurotrophic Factor Increases in Serotonin Reuptake Inhibitor Responders Patients with First-Episode, Drug-Naïve Major Depression.
    Yoshimura R; Okamoto N; Chibaatar E; Natsuyama T; Ikenouchi A
    Biomedicines; 2023 Feb; 11(2):. PubMed ID: 36831119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive factors for responding to sertraline treatment: views from plasma catecholamine metabolites and serotonin transporter polymorphism.
    Umene-Nakano W; Yoshimura R; Ueda N; Suzuki A; Ikenouchi-Sugita A; Hori H; Otani K; Nakamura J
    J Psychopharmacol; 2010 Dec; 24(12):1764-71. PubMed ID: 19825907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The noradrenaline metabolite MHPG is a candidate biomarker between the depressive, remission, and manic states in bipolar disorder I: two long-term naturalistic case reports.
    Kurita M; Nishino S; Numata Y; Okubo Y; Sato T
    Neuropsychiatr Dis Treat; 2015; 11():353-8. PubMed ID: 25709459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of risperidone on plasma catecholamine metabolites and brain-derived neurotrophic factor in patients with bipolar disorders.
    Yoshimura R; Nakano Y; Hori H; Ikenouchi A; Ueda N; Nakamura J
    Hum Psychopharmacol; 2006 Oct; 21(7):433-8. PubMed ID: 17029305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stress at work alters serum brain-derived neurotrophic factor (BDNF) levels and plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) levels in healthy volunteers: BDNF and MHPG as possible biological markers of mental stress?
    Mitoma M; Yoshimura R; Sugita A; Umene W; Hori H; Nakano H; Ueda N; Nakamura J
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):679-85. PubMed ID: 18160197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationships of Cerebrospinal Fluid Monoamine Metabolite Levels With Clinical Variables in Major Depressive Disorder.
    Yoon HS; Hattori K; Ogawa S; Sasayama D; Ota M; Teraishi T; Kunugi H
    J Clin Psychiatry; 2017; 78(8):e947-e956. PubMed ID: 28749090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Molecular Mechanism of Exercise for Treatment of Patients with Major Depression: A Preliminary Report on the Dynamics of Metabolites of Nitric Oxide and Catecholamines.
    Ikenouchi A; Okamoto N; Igata R; Natsuyama T; Yoshimura R
    J Integr Neurosci; 2022 Jun; 21(4):123. PubMed ID: 35864774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aripiprazole altered plasma levels of brain-derived neurotrophic factor and catecholamine metabolites in first-episode untreated Japanese schizophrenia patients.
    Yoshimura R; Hori H; Ikenouchi-Sugita A; Umene-Nakano W; Katsuki A; Hayashi K; Atake K; Tomita M; Nakamura J
    Hum Psychopharmacol; 2012 Jan; 27(1):33-8. PubMed ID: 22213405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum levels of brain-derived neurotrophic factor (BDNF), proBDNF and plasma 3-methoxy-4-hydroxyphenylglycol levels in chronic schizophrenia.
    Yoshimura R; Hori H; Katsuki A; Atake K; Nakamura J
    Ann Gen Psychiatry; 2016; 15():1. PubMed ID: 26770258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The noradrenaline metabolite MHPG is a candidate biomarker from the manic to the remission state in bipolar disorder I: a clinical naturalistic study.
    Kurita M; Nishino S; Numata Y; Okubo Y; Sato T
    PLoS One; 2014; 9(6):e100634. PubMed ID: 24971450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum Brain-derived neurotrophic factor (BDNF): the severity and symptomatic dimensions of depression.
    Jevtović S; Karlović D; Mihaljević-Peleš A; Šerić V; Vrkić N; Jakšić N
    Psychiatr Danub; 2011 Dec; 23(4):363-9. PubMed ID: 22075737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum proBDNF/BDNF and response to fluvoxamine in drug-naïve first-episode major depressive disorder patients.
    Yoshimura R; Kishi T; Hori H; Atake K; Katsuki A; Nakano-Umene W; Ikenouchi-Sugita A; Iwata N; Nakamura J
    Ann Gen Psychiatry; 2014; 13():19. PubMed ID: 25089150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression.
    Hellerstein DJ; Stewart JW; McGrath PJ; Deliyannides DA; Batchelder ST; Black SR; Withers A; O'Shea D; Chen Y
    J Clin Psychiatry; 2012 Jul; 73(7):984-91. PubMed ID: 22901348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.